Literature DB >> 27108841

Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer.

David D Chism1, W Kimryn Rathmell1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27108841      PMCID： PMC4871728          DOI： 10.1038/nrneph.2016.58

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

Review 1.  Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

Authors:  Chris Coppin; Christian Kollmannsberger; Lyly Le; Franz Porzsolt; Timothy J Wilt
Journal:  BJU Int       Date:  2011-09-27       Impact factor: 5.588

2.  A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.

Authors:  Brian Rini; Audrey Goddard; Dejan Knezevic; Tara Maddala; Ming Zhou; Hakan Aydin; Steven Campbell; Paul Elson; Serge Koscielny; Margarita Lopatin; Christer Svedman; Jean-Francois Martini; J Andrew Williams; Virginie Verkarre; Camelia Radulescu; Yann Neuzillet; Isabelle Hemmerlé; Marc Olivier Timsit; Athanasios C Tsiatis; Michael Bonham; Thierry Lebret; Arnaud Mejean; Bernard Escudier
Journal:  Lancet Oncol       Date:  2015-05-12       Impact factor: 41.316

Review 3.  Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch.

Authors:  George N Naumov; Lars A Akslen; Judah Folkman
Journal:  Cell Cycle       Date:  2006-08-15       Impact factor: 4.534

4.  ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.

Authors:  Samira A Brooks; A Rose Brannon; Joel S Parker; Jennifer C Fisher; Oishee Sen; Michael W Kattan; A Ari Hakimi; James J Hsieh; Toni K Choueiri; Pheroze Tamboli; Jodi K Maranchie; Peter Hinds; C Ryan Miller; Matthew E Nielsen; W Kimryn Rathmell
Journal:  Eur Urol       Date:  2014-02-25       Impact factor: 20.096

5.  Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.

Authors:  Carmen J Allegra; Greg Yothers; Michael J O'Connell; Saima Sharif; Nicholas J Petrelli; Samia H Lopa; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-12-10       Impact factor: 44.544

6.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Authors:  Kathy S Albain; William E Barlow; Steven Shak; Gabriel N Hortobagyi; Robert B Livingston; I-Tien Yeh; Peter Ravdin; Roberto Bugarini; Frederick L Baehner; Nancy E Davidson; George W Sledge; Eric P Winer; Clifford Hudis; James N Ingle; Edith A Perez; Kathleen I Pritchard; Lois Shepherd; Julie R Gralow; Carl Yoshizawa; D Craig Allred; C Kent Osborne; Daniel F Hayes
Journal:  Lancet Oncol       Date:  2009-12-10       Impact factor: 41.316

7.  Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

Authors:  David Cameron; Julia Brown; Rebecca Dent; Christian Jackisch; John Mackey; Xavier Pivot; Guenther G Steger; Thomas M Suter; Masakazu Toi; Mahesh Parmar; Rita Laeufle; Young-Hyuck Im; Gilles Romieu; Vernon Harvey; Oleg Lipatov; Tadeusz Pienkowski; Paul Cottu; Arlene Chan; Seock-Ah Im; Peter S Hall; Lida Bubuteishvili-Pacaud; Volkmar Henschel; Regula J Deurloo; Celine Pallaud; Richard Bell
Journal:  Lancet Oncol       Date:  2013-08-07       Impact factor: 41.316

8.  Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Authors:  Naomi B Haas; Judith Manola; Robert G Uzzo; Keith T Flaherty; Christopher G Wood; Christopher Kane; Michael Jewett; Janice P Dutcher; Michael B Atkins; Michael Pins; George Wilding; David Cella; Lynne Wagner; Surena Matin; Timothy M Kuzel; Wade J Sexton; Yu-Ning Wong; Toni K Choueiri; Roberto Pili; Igor Puzanov; Manish Kohli; Walter Stadler; Michael Carducci; Robert Coomes; Robert S DiPaola
Journal:  Lancet       Date:  2016-03-09       Impact factor: 79.321

9.  Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

Authors:  Pippa G Corrie; Andrea Marshall; Janet A Dunn; Mark R Middleton; Paul D Nathan; Martin Gore; Neville Davidson; Steve Nicholson; Charles G Kelly; Maria Marples; Sarah J Danson; Ernest Marshall; Stephen J Houston; Ruth E Board; Ashita M Waterston; Jenny P Nobes; Mark Harries; Satish Kumar; Gemma Young; Paul Lorigan
Journal:  Lancet Oncol       Date:  2014-04-15       Impact factor: 41.316
  9 in total
  3 in total

Review 1.  [Why have tyrosine kinase inhibitors failed in the adjuvant situation and do checkpoint inhibitors make more sense?]

Authors:  Susanne Krege
Journal:  Urologe A       Date:  2020-02       Impact factor: 0.639

Review 2.  Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts.

Authors:  T Sharma; C Tajzler; A Kapoor
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

Review 3.  Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.

Authors:  Andrew T Lenis; Nicholas M Donin; David C Johnson; Izak Faiena; Amirali Salmasi; Alexandra Drakaki; Arie Belldegrun; Allan Pantuck; Karim Chamie
Journal:  J Urol       Date:  2017-05-04       Impact factor: 7.450
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.